Kevin Hicks
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (6)
Year:
2026
Year:
2026
Year:
2025
Introduction The identification of unknown metabolites remains a major challenge in untargeted metabolomics using liquid chromatography-mass spectrometry (LC–MS). This process typically depends on comparing mass spectral or chromatographic data to reference databases or deciphering complex fragmentation in tandem mass spectra. While current machine learning methods can predict metabolite structures using MS/MS (MS2) data, no approaches, to our knowledge, use only mass-to-charge ratio (m/z) and retention time (RT) from LC–MS data. Objective To explore the potential of using the mass-to-charge ratio (m/z) and retention time (RT) from LC–MS data as standalone predictors for metabolite classification and propose a modeling framework which can be implemented internally on standalone datasets. Methods We trained machine learning models on 20 mouse lung adenocarcinoma tumor samples with 7,353 features and validated them on a dataset of 81 samples with 22,000 features. A total of 120 combination of preprocessors and models were assessed. Features were classified as “lipid” or “non-lipid” based on the Human Metabolome Database (HMDB) taxonomy, and model performance was assessed using accuracy, area under the receiver operating characteristic curve (AUC), and area under the precision-recall curve (PR). We replicate the process in an independent dataset generated using human plasma samples. Results We classified untargeted LC–MS features as “lipid” or “non-lipid” per the HMDB super class taxonomy and evaluated model performance. A framework including steps to choose the preprocessors and models for metabolite classification was designed. In our lab, tree-based models demonstrated superior performance across all metrics, achieving high accuracy, AUC, and PR which was consistent with the independent dataset. Conclusion Our results demonstrate that metabolites can be classified as “lipid”, “non-lipid” using only m/z and RT from untargeted LC–MS data, without requiring MS2 spectra. Although this study focused on lipid classification, the approach shows potential for broader application, which warrants further investigation across diverse compound classes, detection methods, and chromatographic conditions.
Year:
2025
FicD regulates Unfolded Protein Response (UPR) through reversible AMPylation and deAMPylation of BiP, an HSP70 chaperone and master regulator of the UPR. FicD activity is regulated by ER-stress, catalyzing BiP AMPylation under low stress conditions to hold inactive chaperone in reserve. In stressed cells, FicD deAMPylates BiP, acutely increasing its active pool to assist in protein folding. Variants in UPR machinery, including those in the FicD gene, are linked to hereditary diseases. Despite the known role of FicD in UPR, in-vivo regulation of its activity remains elusive, and identifying metabolites that alter FicD activity could prove useful pharmaceutically. We applied an unbiased high-throughput screening platform, known as M ass spectrometry Integrated with equilibrium D ialysis for the discovery of A llostery S ystematically (MIDAS), to identify novel small molecule metabolites that might regulate FicD activity. MIDAS revealed interactions between FicD and two mavelonate pathway intermediates : geranyl-pyrophosphate and farnesyl-pyrophosphate. Biochemical characterization indicates that both potently inhibit FicD-mediated AMPylation and deAMPylation. The crystal structure of FicD bound to farnesyl-pyrophosphate demonstrates a competitive inhibition mechanism, with the pyrophosphate adopting the alpha and beta phosphate positions of ATP and the hydrocarbon chain filling the nucleoside pocket. FicD variants previously appeared as biochemically indistinguishable, yet lead to different human pathologies. We demonstrate farnesyl-pyrophosphate inhibits FicD R374H and FicD R374C variants implicated in causing hereditary spastic paraplegia, but not the FicD R371S variant associated with neonatal diabetes. This study furthers our understanding of FicD inhibitors and distinguishes disease causing variants, providing insight into pharmacological targeting of UPR activity. Significance Statement FicD regulates UPR signaling in metazoans by fine-tuning BiP chaperone capacity. Therefore, targeting FicD activity may be a tractable method of altering UPR signaling for therapeutic benefit. We identify geranyl- and farnesyl-pyrophosphate as specific FicD inhibitors. Notably, these small molecules differentially inhibit disease-causing variants of FicD. A structure of farnesyl-pyrophosphate bound to the FicD active site helps explain the differential inhibition of pathogenic variants and provides insight into interactions that can be differentially exploited for modifying FicD activity. Their composition provides a novel chemical foundation for future drug development efforts targeting FicD activity.
Year:
2025
Year:
2023
Collaborators (10)
Kim Orth
Investigator/Professor
-
Tamara J. O’Connor
Associate Professor
Johns Hopkins University School of Medicine
James Wohlschlegel
Professor
University of California, Los Angeles
Dean Tolan
Professor
Boston University
Andrew VanDemark
University of Pittsburgh
Jared Rutter
Professor
University of Utah
Heidi Schubert
Research Assoc. Professor
University of Utah
Amit Reddi
Professor
Georgia Institute of Technology
Amanda Casey
Research Assistant Professor
University of Texas Southwestern Medical Center
Ahmad Cluntun
Assistant Professor
Rutgers University
Make your next move.
Prepare your application
Review drafts before you send them.